Drug Profile
Mitiperstat - AstraZeneca
Alternative Names: AZD-4831Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; University of Cologne
- Class Amines; Cardiotonics; Cardiovascular therapies; Chlorophenols; Heart failure therapies; Hepatoprotectants; Organic sulfur compounds; Pyrimidinones; Pyrroles; Small molecules
- Mechanism of Action Peroxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Heart failure
- Phase II Cardiomyopathies; Chronic obstructive pulmonary disease; Non-alcoholic steatohepatitis; Pulmonary hypertension
Most Recent Events
- 04 Apr 2024 AstraZeneca completes phase II trials in Non-alcoholic steatohepatitis in Spain, Sweden, Portugal, Norway, Mexico, Italy, Denmark, Argentina, USA (PO)(NCT05638737)
- 27 Mar 2024 AstraZeneca completes the Phase-II/III clinical trials in Heart failure in Sweden, Netherlands, Bulgaria, Denmark, Australia, Brazil, Czech Republic, Belgium, Canada, France, Hungary, Japan, Poland, Russia, Slovakia, Taiwan, Turkey (PO) (NCT04986202) (EudraCT2020-005844-47)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in United Kingdom (PO)